PhaseV launched AI Conductor, an offering designed to automate major parts of the clinical development workflow, from protocol work through compliance and regulatory submission readiness. Boston-based PhaseV said the platform harmonizes disparate trial datasets and supports ICH E9-aligned work, including case report generation, while integrating into its existing AI clinical trial platform. The company described the goal as converting disconnected manual tasks into a synchronized process. PhaseV also disclosed venture backing behind the launch, citing $54 million in total venture funding associated with its broader AI platform expansion, following a €50 million fundraising round last May. The launch arrives as other vendors roll out AI-based trial compliance tools—signaling continued pressure to reduce operational bottlenecks in trial documentation and data preparation.